<DOC>
	<DOCNO>NCT00244231</DOCNO>
	<brief_summary>To assess efficacy safety Nidadd ( extended-release niacin ) patient hyperlipidemia .</brief_summary>
	<brief_title>Efficacy Safety Study Nidadd Management Hyperlipidemia</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter study . A total least 50 patient recruit achieve 40 evaluable patient require assess safety efficacy escalate dos extended-release Nidadd hyperlipidemic patient . 1 . The trial begin measurement baseline lipid level . Fasting blood sample collect screen treatment visit ( except visit 3 ) lipid analysis safety monitoring . Chemistry laboratory test hematological test perform periodically . Patient ’ diet education give dietician appropriately trained counselor visit 1 2 . 2 . Patients take lipid-modifying drug require go 4-week washout / diet-controlled period prior randomization ( visit 2 ) . 3 . Treatment duration 16 week total : Patients randomize treatment Nidadd receive 500 mg first 8 week medication period . For another 8 week , dose increased 1000 mg maintain end study . The patient control group take placebo fashion Nidadd group throughout entire 16 week . 4 . The primary measure efficacy change baseline serum HDL-c level . Secondary measure efficacy change baseline serum total cholesterol , LDL-c , triglyceride . 5 . Safety tolerability evaluate adverse event , number patient prematurely discontinue trial adverse event , laboratory measure .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . Male female subject age 20 75 year . 2 . An least 4 week washout / dietcontrolled period study entry require . 3 . HDL cholesterol &lt; 40 mg/dL male &lt; 50 mg/dL female ; triglyceride level ≧ 200 mg/dL . 4 . Being mentally competent able understand study requirement sign inform consent form . 1 . Total cholesterol ≧ 300 mg/dL ; triglyceride level ≧ 1000 mg/dL . 2 . Having FPG level great 180 mg/dL 4week washout / diet control period . 3 . Type1 diabetes mellitus ; type2 diabetes mellitus without stable ( fix dose ) medication . 4 . Pregnant lactate woman woman childbearing potential practicing reliable form birth control ( either IUD stable usage oral contraceptive ) . 5 . Concomitant steroid therapy . 6 . Received lipidmodifying agent within four week washout / dietcontrolled period . 7 . With clinically significant cardiac arrhythmia serious cardiac abnormality ; receive coronary artery bypass graft percutaneous transluminal coronary angioplasty within 6 month prior study entry . 8 . Malignant tumor ( except squamous/basal cell skin cancer ) , chronic terminal disease ( e.g . AIDS , liver cirrhosis , etc . ) within past 5 year . 9 . With disorder condition , opinion investigator preclude successful compliant participation study . 10 . Nephrotic syndrome renal dysfunction , serum creatinine &gt; 2.0 mg/dl ; active hepatic dysfunction , SGPT , SGOT , gGT , alkaline phosphatase value great 2 time upper limit normal . 11 . With pancreatitis , gallbladder disease , active peptic ulcer disease within 6 month . 12 . Active gouty arthritis . 13 . Taken investigational drug within one month prior study entry . 14 . With known hypersensitivity niacin . 15 . With history alcohol and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Niacin</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>